Our new oncology patent WO2022180080 was approved and is already available in the WIPO database. The patent protects a new generation of antitumor agents with high activity, low toxicity and a favorable pharmacological profile.
FHP continues its work on clinical candidates with its improved generations of patented compounds, active against important targets such as Lung Cancer, Triple Negative Breast Cancer and Liver Cancer.